Eisai joins with other biopharma companies launched Access Accelerated. This is a global initiative to advance access to non-communicable diseases care and prevention in low and lower middle income countries. NCDs have reached a crisis point particularly in countries with lower and middle income where about 80 percent of NCD related deaths happen.
Access Accelerated is partnered with the Union for International Cancer Control (UICC) and the World Bank Group. The aim of this partnership is to work towards a United Nations Sustainable Development Goal target to reduce NCD-related premature deaths by one-third by the year 2030. Ian Read, Chief Executive Officer of Pfizer and president of The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) states that Access Accelerated will work towards a shared vision that no person dies prematurely from a preventable, treatable disease.
According to Read, if the current trend in NCDs is not reversed, there is a real possibility that we will undermine the progress we have made in health around the world. In order to reach the goal, new partnerships must be formed, learn quickly and enable countries to deal with NCDs by advancing resources and knowledge.
Access Accelerated ins building on more than 100 longstanding individual company investments to advance NCD care in developing countries. Access Accelerated will bring transparency and additional accountability to existing efforts. It will also be placing emphasis on addressing barriers to NCD prevention, care and treatment. Independent experts from Boston University will be supporting by evaluating the efforts to establish measures of effectiveness, build a framework for progress and deliver reports according to an article by PR Newswire.
Eisai has been running various initiatives in countries to improve access. Efforts include Alzheimer's disease awareness and early detection in China, the introduction of an affordable pricing model of global metastatic breast cancer agent HALAVEN in seven Asian countries including Thailand, the Philippines and India where the prices are tiered and set at several levels in accordance with the income of levels of patients.
Eisai's CEO Haruo Naito stated that one of the missions of modern pharmaceutical industry is to make drugs accessible to all patients regardless of their socioeconomic status. Eisai joins hands with other biopharmaceutical companies and is pleased to take part in Access Accelerated to help address the medical and social needs of patients and their caregivers. Pursuing solutions for global access challenges is both a responsibility and long term investment for Eisai according to an article by Yahoo Finance.
